Liza Laws, Author at Labiotech.eu

News and Trends 3 Nov 2022

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Meletios Therapeutics wins €5.2M European Commission funding for SARS research

Meletios Therapeutics, a French biotech company, announced today (November 2) that it has been named one of 75 winners of the European Innovation Council (EIC) Accelerator program and will receive €5.2 million ($5.1 million) in funding from the European Commission. The company specializes in the research and development of antiviral treatments and says the funding […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

The Native Antigen Company expands range of Omicron antigens to include BA.5 variant

The Native Antigen Company today (November 2) announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant. The company, part of LGC Clinical Diagnostics, is a supplier of reagents enabling research into vaccines and diagnostics for emerging endemic infectious diseases. The new range of RBD (receptor binding domain) antigens […]

November 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

AELIX Therapeutics publishes positive data on its HIV vaccine

Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal. The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection. Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Enzyre secures €12M series A funding to help hemophilia patients test from home

Dutch company, Enzyre, which is developing ambulant diagnostic technology for blood coagulation testing, today (November 2) announced it has successfully raised €12 million ($11.9 million) in series A financing. The round was led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as technology partner and existing investors, Takeda Ventures and […]

November 2, 2022 - 3 minutesmins - By Liza Laws

More News! 31 Oct 2022

New drug application for chronic kidney disease sparks $35M milestone payment

A submission has been made for a new drug application by Japanese Kyowa Kirin Co. Ltd. for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD). The company has submitted the application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor, which helps those with CKD on dialysis. Ardelyx, Inc. […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

First patient enrolled and dosed on expansion phase of cancer treatment trial

The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […]

October 31, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

Researchers develop efficient nanovaccine delivery system boosting cellular immunity

A research group has successfully developed a new nanovaccine delivery system, to strongly activate cellular immunity, using one-tenth of the amount of antigen that was previously required. Led by Eiji Yuba, an associate professor at the Graduate School of Engineering at Osaka Metropolitan University in Japan, the group has been developing been developing the […]

October 31, 2022 - 3 minutesmins - By Liza Laws

More News! 31 Oct 2022

Drug discovery company signs exclusive license to use university’s technology

A drug discovery and development company using deubiquitylase (DUB) modulators as therapeutics for areas of high unmet needs has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. Sheelagh Frame, is chief scientific officer, at Ubiquigent, the company that has signed the agreement. She said: “We are delighted to have […]

October 31, 2022 - 3 minutesmins - By Liza Laws

More News! 28 Oct 2022

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

A whole new level of control of cancer gene activity within tumors, has been described by researchers as ‘dark matter’. It was recently discovered and published in two major studies at the same time in Nature that cancers can evolve to become more aggressive without relying on DNA mutations. Testing cancers for just the DNA […]

October 28, 2022 - 6 minutesmins - By Liza Laws

More News! 26 Oct 2022

Study shows ability to develop and apply targeted treatment in head and neck cancers

A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas are very heterogeneous and have a lack of prognostic markers – a significant impediment to personalized treatment. The joint study by MedUni Vienna and the […]

October 26, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Meletios Therapeutics wins €5.2M European Commission funding for SARS research

The Native Antigen Company expands range of Omicron antigens to include BA.5 variant

AELIX Therapeutics publishes positive data on its HIV vaccine

Enzyre secures €12M series A funding to help hemophilia patients test from home

New drug application for chronic kidney disease sparks $35M milestone payment

First patient enrolled and dosed on expansion phase of cancer treatment trial

Researchers develop efficient nanovaccine delivery system boosting cellular immunity

Drug discovery company signs exclusive license to use university’s technology

‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say

Study shows ability to develop and apply targeted treatment in head and neck cancers

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Articles by Liza Laws

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!